ABCB1 is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ABCB1 status and ovarian carcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

ABL2 is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ABL2 status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

ACVR1B is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ACVR1B status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

AKT1 is an inclusion eligibility criterion in 2 clinical trials for ovarian carcinoma, of which 2 are open and 0 are closed. Of the trials that contain AKT1 status and ovarian carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

AKT2 is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains AKT2 status and ovarian carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

AKT3 is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains AKT3 status and ovarian carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

ALK is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ALK status and ovarian carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

APC is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 0 are open and 1 is closed. Of the trial that contains APC status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

ARAF is an inclusion eligibility criterion in 2 clinical trials for ovarian carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ARAF status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

ARID1A is an inclusion eligibility criterion in 4 clinical trials for ovarian carcinoma, of which 3 are open and 1 is closed. Of the trials that contain ARID1A status and ovarian carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 1 is phase 1/phase 2 (0 open) [3].

ASXL1 is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ASXL1 status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

ATM is an inclusion eligibility criterion in 20 clinical trials for ovarian carcinoma, of which 15 are open and 5 are closed. Of the trials that contain ATM status and ovarian carcinoma as inclusion criteria, 6 are phase 1 (4 open), 4 are phase 1/phase 2 (3 open), 8 are phase 2 (7 open), 1 is phase 3 (0 open), and 1 is phase 4 (1 open) [3].

ATR is an inclusion eligibility criterion in 15 clinical trials for ovarian carcinoma, of which 10 are open and 5 are closed. Of the trials that contain ATR status and ovarian carcinoma as inclusion criteria, 6 are phase 1 (4 open), 2 are phase 1/phase 2 (1 open), 6 are phase 2 (5 open), and 1 is phase 3 (0 open) [3].

ATRX is an inclusion eligibility criterion in 4 clinical trials for ovarian carcinoma, of which 3 are open and 1 is closed. Of the trials that contain ATRX status and ovarian carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 1 is phase 1/phase 2 (0 open) [3].

BACH1 is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BACH1 status and ovarian carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

BARD1 is an inclusion eligibility criterion in 17 clinical trials for ovarian carcinoma, of which 13 are open and 4 are closed. Of the trials that contain BARD1 status and ovarian carcinoma as inclusion criteria, 5 are phase 1 (4 open), 3 are phase 1/phase 2 (2 open), 7 are phase 2 (6 open), 1 is phase 3 (0 open), and 1 is phase 4 (1 open) [3].

BCL2 is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BCL2 status and ovarian carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

BCL6 is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BCL6 status and ovarian carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

BLM is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 0 are open and 1 is closed. Of the trial that contains BLM status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

BRAF is an inclusion eligibility criterion in 6 clinical trials for ovarian carcinoma, of which 5 are open and 1 is closed. Of the trials that contain BRAF status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 3 are phase 2 (3 open) [3].

BRCA1 is an inclusion eligibility criterion in 40 clinical trials for ovarian carcinoma, of which 31 are open and 9 are closed. Of the trials that contain BRCA1 status and ovarian carcinoma as inclusion criteria, 3 are early phase 1 (3 open), 10 are phase 1 (7 open), 8 are phase 1/phase 2 (7 open), 14 are phase 2 (10 open), 4 are phase 3 (3 open), and 1 is phase 4 (1 open) [3].

BRCA2 is an inclusion eligibility criterion in 40 clinical trials for ovarian carcinoma, of which 31 are open and 9 are closed. Of the trials that contain BRCA2 status and ovarian carcinoma as inclusion criteria, 3 are early phase 1 (3 open), 10 are phase 1 (7 open), 8 are phase 1/phase 2 (7 open), 14 are phase 2 (10 open), 4 are phase 3 (3 open), and 1 is phase 4 (1 open) [3].

BRIP1 is an inclusion eligibility criterion in 17 clinical trials for ovarian carcinoma, of which 13 are open and 4 are closed. Of the trials that contain BRIP1 status and ovarian carcinoma as inclusion criteria, 5 are phase 1 (4 open), 3 are phase 1/phase 2 (2 open), 7 are phase 2 (6 open), 1 is phase 3 (0 open), and 1 is phase 4 (1 open) [3].

C11orf30 is an inclusion eligibility criterion in 4 clinical trials for ovarian carcinoma, of which 3 are open and 1 is closed. Of the trials that contain C11orf30 status and ovarian carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 1 is phase 1/phase 2 (0 open) [3].

CCND1 is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 status and ovarian carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CCNE1 is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CCNE1 status and ovarian carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

CCNE2 is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CCNE2 status and ovarian carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

CDK12 is an inclusion eligibility criterion in 18 clinical trials for ovarian carcinoma, of which 13 are open and 5 are closed. Of the trials that contain CDK12 status and ovarian carcinoma as inclusion criteria, 6 are phase 1 (4 open), 3 are phase 1/phase 2 (2 open), 7 are phase 2 (6 open), 1 is phase 3 (0 open), and 1 is phase 4 (1 open) [3].

CDK4 is an inclusion eligibility criterion in 2 clinical trials for ovarian carcinoma, of which 2 are open and 0 are closed. Of the trials that contain CDK4 status and ovarian carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].

CDK6 is an inclusion eligibility criterion in 2 clinical trials for ovarian carcinoma, of which 2 are open and 0 are closed. Of the trials that contain CDK6 status and ovarian carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].

CDKN1A is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CDKN1A status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

CDKN1B is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CDKN1B status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

CDKN2A is an inclusion eligibility criterion in 2 clinical trials for ovarian carcinoma, of which 1 is open and 1 is closed. Of the trials that contain CDKN2A status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].

CHD4 is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CHD4 status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

CHEK1 is an inclusion eligibility criterion in 16 clinical trials for ovarian carcinoma, of which 12 are open and 4 are closed. Of the trials that contain CHEK1 status and ovarian carcinoma as inclusion criteria, 5 are phase 1 (4 open), 3 are phase 1/phase 2 (2 open), 6 are phase 2 (5 open), 1 is phase 3 (0 open), and 1 is phase 4 (1 open) [3].

CHEK2 is an inclusion eligibility criterion in 17 clinical trials for ovarian carcinoma, of which 13 are open and 4 are closed. Of the trials that contain CHEK2 status and ovarian carcinoma as inclusion criteria, 5 are phase 1 (4 open), 3 are phase 1/phase 2 (2 open), 7 are phase 2 (6 open), 1 is phase 3 (0 open), and 1 is phase 4 (1 open) [3].

CRKL is an inclusion eligibility criterion in 2 clinical trials for ovarian carcinoma, of which 2 are open and 0 are closed. Of the trials that contain CRKL status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

CSF1R is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CSF1R status and ovarian carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CYLD is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CYLD status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

DICER1 is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 0 are open and 1 is closed. Of the trial that contains DICER1 status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

DNMT3A is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 0 are open and 1 is closed. Of the trial that contains DNMT3A status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

EGFR is an inclusion eligibility criterion in 2 clinical trials for ovarian carcinoma, of which 2 are open and 0 are closed. Of the trials that contain EGFR status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

EPCAM is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EPCAM status and ovarian carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ERBB2 is an inclusion eligibility criterion in 7 clinical trials for ovarian carcinoma, of which 5 are open and 2 are closed. Of the trials that contain ERBB2 status and ovarian carcinoma as inclusion criteria, 4 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [3].

ERBB3 is an inclusion eligibility criterion in 2 clinical trials for ovarian carcinoma, of which 1 is open and 1 is closed. Of the trials that contain ERBB3 status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].

ERCC2 is an inclusion eligibility criterion in 4 clinical trials for ovarian carcinoma, of which 3 are open and 1 is closed. Of the trials that contain ERCC2 status and ovarian carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 1 is phase 1/phase 2 (0 open) [3].

ERCC3 is an inclusion eligibility criterion in 4 clinical trials for ovarian carcinoma, of which 3 are open and 1 is closed. Of the trials that contain ERCC3 status and ovarian carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 1 is phase 1/phase 2 (0 open) [3].

ERCC4 is an inclusion eligibility criterion in 4 clinical trials for ovarian carcinoma, of which 3 are open and 1 is closed. Of the trials that contain ERCC4 status and ovarian carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 1 is phase 1/phase 2 (0 open) [3].

ERCC5 is an inclusion eligibility criterion in 4 clinical trials for ovarian carcinoma, of which 3 are open and 1 is closed. Of the trials that contain ERCC5 status and ovarian carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 1 is phase 1/phase 2 (0 open) [3].

ERCC6 is an inclusion eligibility criterion in 4 clinical trials for ovarian carcinoma, of which 3 are open and 1 is closed. Of the trials that contain ERCC6 status and ovarian carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 1 is phase 1/phase 2 (0 open) [3].

EXO1 is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EXO1 status and ovarian carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

EZH2 is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 0 are open and 1 is closed. Of the trial that contains EZH2 status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

FANCA is an inclusion eligibility criterion in 16 clinical trials for ovarian carcinoma, of which 12 are open and 4 are closed. Of the trials that contain FANCA status and ovarian carcinoma as inclusion criteria, 5 are phase 1 (4 open), 2 are phase 1/phase 2 (1 open), 8 are phase 2 (7 open), and 1 is phase 3 (0 open) [3].

FANCB is an inclusion eligibility criterion in 14 clinical trials for ovarian carcinoma, of which 10 are open and 4 are closed. Of the trials that contain FANCB status and ovarian carcinoma as inclusion criteria, 5 are phase 1 (4 open), 2 are phase 1/phase 2 (1 open), 6 are phase 2 (5 open), and 1 is phase 3 (0 open) [3].

FANCC is an inclusion eligibility criterion in 14 clinical trials for ovarian carcinoma, of which 10 are open and 4 are closed. Of the trials that contain FANCC status and ovarian carcinoma as inclusion criteria, 5 are phase 1 (4 open), 2 are phase 1/phase 2 (1 open), 6 are phase 2 (5 open), and 1 is phase 3 (0 open) [3].

FANCD2 is an inclusion eligibility criterion in 14 clinical trials for ovarian carcinoma, of which 10 are open and 4 are closed. Of the trials that contain FANCD2 status and ovarian carcinoma as inclusion criteria, 5 are phase 1 (4 open), 2 are phase 1/phase 2 (1 open), 6 are phase 2 (5 open), and 1 is phase 3 (0 open) [3].

FANCE is an inclusion eligibility criterion in 14 clinical trials for ovarian carcinoma, of which 10 are open and 4 are closed. Of the trials that contain FANCE status and ovarian carcinoma as inclusion criteria, 5 are phase 1 (4 open), 2 are phase 1/phase 2 (1 open), 6 are phase 2 (5 open), and 1 is phase 3 (0 open) [3].

FANCF is an inclusion eligibility criterion in 14 clinical trials for ovarian carcinoma, of which 10 are open and 4 are closed. Of the trials that contain FANCF status and ovarian carcinoma as inclusion criteria, 5 are phase 1 (4 open), 2 are phase 1/phase 2 (1 open), 6 are phase 2 (5 open), and 1 is phase 3 (0 open) [3].

FANCG is an inclusion eligibility criterion in 14 clinical trials for ovarian carcinoma, of which 10 are open and 4 are closed. Of the trials that contain FANCG status and ovarian carcinoma as inclusion criteria, 5 are phase 1 (4 open), 2 are phase 1/phase 2 (1 open), 6 are phase 2 (5 open), and 1 is phase 3 (0 open) [3].

FANCI is an inclusion eligibility criterion in 14 clinical trials for ovarian carcinoma, of which 10 are open and 4 are closed. Of the trials that contain FANCI status and ovarian carcinoma as inclusion criteria, 5 are phase 1 (4 open), 2 are phase 1/phase 2 (1 open), 6 are phase 2 (5 open), and 1 is phase 3 (0 open) [3].

FANCL is an inclusion eligibility criterion in 16 clinical trials for ovarian carcinoma, of which 12 are open and 4 are closed. Of the trials that contain FANCL status and ovarian carcinoma as inclusion criteria, 5 are phase 1 (4 open), 3 are phase 1/phase 2 (2 open), 6 are phase 2 (5 open), 1 is phase 3 (0 open), and 1 is phase 4 (1 open) [3].

FANCM is an inclusion eligibility criterion in 14 clinical trials for ovarian carcinoma, of which 10 are open and 4 are closed. Of the trials that contain FANCM status and ovarian carcinoma as inclusion criteria, 5 are phase 1 (4 open), 2 are phase 1/phase 2 (1 open), 6 are phase 2 (5 open), and 1 is phase 3 (0 open) [3].

FGF19 is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 0 are open and 1 is closed. Of the trial that contains FGF19 status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

FGF4 is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 0 are open and 1 is closed. Of the trial that contains FGF4 status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

FGFR1 is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR1 status and ovarian carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FGFR2 is an inclusion eligibility criterion in 2 clinical trials for ovarian carcinoma, of which 1 is open and 1 is closed. Of the trials that contain FGFR2 status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].

FGFR3 is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and ovarian carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FLT1 is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FLT1 status and ovarian carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FLT3 is an inclusion eligibility criterion in 2 clinical trials for ovarian carcinoma, of which 1 is open and 1 is closed. Of the trials that contain FLT3 status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].

FLT4 is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FLT4 status and ovarian carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

GATA3 is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 0 are open and 1 is closed. Of the trial that contains GATA3 status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

HDAC1 is an inclusion eligibility criterion in 4 clinical trials for ovarian carcinoma, of which 3 are open and 1 is closed. Of the trials that contain HDAC1 status and ovarian carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 1 is phase 1/phase 2 (0 open) [3].

HDAC2 is an inclusion eligibility criterion in 4 clinical trials for ovarian carcinoma, of which 3 are open and 1 is closed. Of the trials that contain HDAC2 status and ovarian carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 1 is phase 1/phase 2 (0 open) [3].

HGF is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 0 are open and 1 is closed. Of the trial that contains HGF status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

HRAS is an inclusion eligibility criterion in 3 clinical trials for ovarian carcinoma, of which 2 are open and 1 is closed. Of the trials that contain HRAS status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [3].

IDH1 is an inclusion eligibility criterion in 2 clinical trials for ovarian carcinoma, of which 1 is open and 1 is closed. Of the trials that contain IDH1 status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].

IDH2 is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains IDH2 status and ovarian carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

KDM6A is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 0 are open and 1 is closed. Of the trial that contains KDM6A status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

KDR is an inclusion eligibility criterion in 2 clinical trials for ovarian carcinoma, of which 1 is open and 1 is closed. Of the trials that contain KDR status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].

KEAP1 is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 0 are open and 1 is closed. Of the trial that contains KEAP1 status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

KIT is an inclusion eligibility criterion in 2 clinical trials for ovarian carcinoma, of which 1 is open and 1 is closed. Of the trials that contain KIT status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].

KMT2D is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 0 are open and 1 is closed. Of the trial that contains KMT2D status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

KRAS is an inclusion eligibility criterion in 8 clinical trials for ovarian carcinoma, of which 5 are open and 3 are closed. Of the trials that contain KRAS status and ovarian carcinoma as inclusion criteria, 4 are phase 1 (3 open), 3 are phase 1/phase 2 (2 open), and 1 is phase 2 (0 open) [3].

MAGI2 is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MAGI2 status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

MAP2K1 is an inclusion eligibility criterion in 2 clinical trials for ovarian carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MAP2K1 status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

MAP2K2 is an inclusion eligibility criterion in 2 clinical trials for ovarian carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MAP2K2 status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

MAP2K4 is an inclusion eligibility criterion in 2 clinical trials for ovarian carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MAP2K4 status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

MAP3K1 is an inclusion eligibility criterion in 3 clinical trials for ovarian carcinoma, of which 2 are open and 1 is closed. Of the trials that contain MAP3K1 status and ovarian carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

MAPK1 is an inclusion eligibility criterion in 2 clinical trials for ovarian carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MAPK1 status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

MCL1 is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MCL1 status and ovarian carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MCPH1 is an inclusion eligibility criterion in 10 clinical trials for ovarian carcinoma, of which 6 are open and 4 are closed. Of the trials that contain MCPH1 status and ovarian carcinoma as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (1 open), 5 are phase 2 (4 open), and 1 is phase 3 (0 open) [3].

MDM2 is an inclusion eligibility criterion in 4 clinical trials for ovarian carcinoma, of which 3 are open and 1 is closed. Of the trials that contain MDM2 status and ovarian carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 1 is phase 1/phase 2 (0 open) [3].

MDM4 is an inclusion eligibility criterion in 4 clinical trials for ovarian carcinoma, of which 3 are open and 1 is closed. Of the trials that contain MDM4 status and ovarian carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 1 is phase 1/phase 2 (0 open) [3].

MED12 is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MED12 status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

MET is an inclusion eligibility criterion in 2 clinical trials for ovarian carcinoma, of which 1 is open and 1 is closed. Of the trials that contain MET status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].

MLF1 is an inclusion eligibility criterion in 4 clinical trials for ovarian carcinoma, of which 3 are open and 1 is closed. Of the trials that contain MLF1 status and ovarian carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 1 is phase 1/phase 2 (0 open) [3].

MLH1 is an inclusion eligibility criterion in 5 clinical trials for ovarian carcinoma, of which 4 are open and 1 is closed. Of the trials that contain MLH1 status and ovarian carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [3].

MLH3 is an inclusion eligibility criterion in 5 clinical trials for ovarian carcinoma, of which 4 are open and 1 is closed. Of the trials that contain MLH3 status and ovarian carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [3].

MRE11A is an inclusion eligibility criterion in 15 clinical trials for ovarian carcinoma, of which 11 are open and 4 are closed. Of the trials that contain MRE11A status and ovarian carcinoma as inclusion criteria, 5 are phase 1 (4 open), 2 are phase 1/phase 2 (1 open), 7 are phase 2 (6 open), and 1 is phase 3 (0 open) [3].

MSH2 is an inclusion eligibility criterion in 6 clinical trials for ovarian carcinoma, of which 4 are open and 2 are closed. Of the trials that contain MSH2 status and ovarian carcinoma as inclusion criteria, 4 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [3].

MSH3 is an inclusion eligibility criterion in 5 clinical trials for ovarian carcinoma, of which 4 are open and 1 is closed. Of the trials that contain MSH3 status and ovarian carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [3].

MSH6 is an inclusion eligibility criterion in 6 clinical trials for ovarian carcinoma, of which 4 are open and 2 are closed. Of the trials that contain MSH6 status and ovarian carcinoma as inclusion criteria, 4 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [3].

MST1R is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MST1R status and ovarian carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MTOR is an inclusion eligibility criterion in 2 clinical trials for ovarian carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MTOR status and ovarian carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

MUTYH is an inclusion eligibility criterion in 4 clinical trials for ovarian carcinoma, of which 3 are open and 1 is closed. Of the trials that contain MUTYH status and ovarian carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 1 is phase 1/phase 2 (0 open) [3].

MYC is an inclusion eligibility criterion in 4 clinical trials for ovarian carcinoma, of which 2 are open and 2 are closed. Of the trials that contain MYC status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 3 are phase 1/phase 2 (2 open) [3].

NBN is an inclusion eligibility criterion in 16 clinical trials for ovarian carcinoma, of which 12 are open and 4 are closed. Of the trials that contain NBN status and ovarian carcinoma as inclusion criteria, 5 are phase 1 (4 open), 2 are phase 1/phase 2 (1 open), 8 are phase 2 (7 open), and 1 is phase 3 (0 open) [3].

NF1 is an inclusion eligibility criterion in 3 clinical trials for ovarian carcinoma, of which 2 are open and 1 is closed. Of the trials that contain NF1 status and ovarian carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

NF2 is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 0 are open and 1 is closed. Of the trial that contains NF2 status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

NOTCH1 is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 0 are open and 1 is closed. Of the trial that contains NOTCH1 status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

NOTCH2 is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 0 are open and 1 is closed. Of the trial that contains NOTCH2 status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

NPM1 is an inclusion eligibility criterion in 4 clinical trials for ovarian carcinoma, of which 3 are open and 1 is closed. Of the trials that contain NPM1 status and ovarian carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 1 is phase 1/phase 2 (0 open) [3].

NRAS is an inclusion eligibility criterion in 4 clinical trials for ovarian carcinoma, of which 2 are open and 2 are closed. Of the trials that contain NRAS status and ovarian carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [3].

NRG1 is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NRG1 status and ovarian carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

NSD1 is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 0 are open and 1 is closed. Of the trial that contains NSD1 status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

NTRK1 is an inclusion eligibility criterion in 2 clinical trials for ovarian carcinoma, of which 2 are open and 0 are closed. Of the trials that contain NTRK1 status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

NTRK2 is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NTRK2 status and ovarian carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

NTRK3 is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NTRK3 status and ovarian carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PALB2 is an inclusion eligibility criterion in 19 clinical trials for ovarian carcinoma, of which 15 are open and 4 are closed. Of the trials that contain PALB2 status and ovarian carcinoma as inclusion criteria, 5 are phase 1 (4 open), 4 are phase 1/phase 2 (3 open), 8 are phase 2 (7 open), 1 is phase 3 (0 open), and 1 is phase 4 (1 open) [3].

PARP1 is an inclusion eligibility criterion in 4 clinical trials for ovarian carcinoma, of which 3 are open and 1 is closed. Of the trials that contain PARP1 status and ovarian carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 1 is phase 1/phase 2 (0 open) [3].

PARP2 is an inclusion eligibility criterion in 4 clinical trials for ovarian carcinoma, of which 3 are open and 1 is closed. Of the trials that contain PARP2 status and ovarian carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 1 is phase 1/phase 2 (0 open) [3].

PCNA is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PCNA status and ovarian carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PDGFRA is an inclusion eligibility criterion in 2 clinical trials for ovarian carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PDGFRA status and ovarian carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

PDGFRB is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB status and ovarian carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PIK3C2B is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PIK3C2B status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

PIK3CA is an inclusion eligibility criterion in 3 clinical trials for ovarian carcinoma, of which 2 are open and 1 is closed. Of the trials that contain PIK3CA status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

PIK3CB is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PIK3CB status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

PIK3CG is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CG status and ovarian carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PIK3R1 is an inclusion eligibility criterion in 2 clinical trials for ovarian carcinoma, of which 1 is open and 1 is closed. Of the trials that contain PIK3R1 status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (1 open) [3].

PIK3R2 is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3R2 status and ovarian carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PMS1 is an inclusion eligibility criterion in 5 clinical trials for ovarian carcinoma, of which 4 are open and 1 is closed. Of the trials that contain PMS1 status and ovarian carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [3].

PMS2 is an inclusion eligibility criterion in 5 clinical trials for ovarian carcinoma, of which 4 are open and 1 is closed. Of the trials that contain PMS2 status and ovarian carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [3].

POLD1 is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLD1 status and ovarian carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

POLE is an inclusion eligibility criterion in 5 clinical trials for ovarian carcinoma, of which 4 are open and 1 is closed. Of the trials that contain POLE status and ovarian carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [3].

PPP2R1A is an inclusion eligibility criterion in 4 clinical trials for ovarian carcinoma, of which 3 are open and 1 is closed. Of the trials that contain PPP2R1A status and ovarian carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 1 is phase 1/phase 2 (0 open) [3].

PPP2R2A is an inclusion eligibility criterion in 6 clinical trials for ovarian carcinoma, of which 5 are open and 1 is closed. Of the trials that contain PPP2R2A status and ovarian carcinoma as inclusion criteria, 3 are phase 1 (3 open), 2 are phase 1/phase 2 (1 open), and 1 is phase 4 (1 open) [3].

PTCH1 is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PTCH1 status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

PTEN is an inclusion eligibility criterion in 12 clinical trials for ovarian carcinoma, of which 7 are open and 5 are closed. Of the trials that contain PTEN status and ovarian carcinoma as inclusion criteria, 3 are phase 1 (1 open), 3 are phase 1/phase 2 (2 open), 5 are phase 2 (4 open), and 1 is phase 3 (0 open) [3].

PTPN11 is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PTPN11 status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

RAD50 is an inclusion eligibility criterion in 14 clinical trials for ovarian carcinoma, of which 10 are open and 4 are closed. Of the trials that contain RAD50 status and ovarian carcinoma as inclusion criteria, 5 are phase 1 (4 open), 2 are phase 1/phase 2 (1 open), 6 are phase 2 (5 open), and 1 is phase 3 (0 open) [3].

RAD51 is an inclusion eligibility criterion in 15 clinical trials for ovarian carcinoma, of which 11 are open and 4 are closed. Of the trials that contain RAD51 status and ovarian carcinoma as inclusion criteria, 5 are phase 1 (4 open), 2 are phase 1/phase 2 (1 open), 7 are phase 2 (6 open), and 1 is phase 3 (0 open) [3].

RAD51B is an inclusion eligibility criterion in 17 clinical trials for ovarian carcinoma, of which 13 are open and 4 are closed. Of the trials that contain RAD51B status and ovarian carcinoma as inclusion criteria, 5 are phase 1 (4 open), 3 are phase 1/phase 2 (2 open), 7 are phase 2 (6 open), 1 is phase 3 (0 open), and 1 is phase 4 (1 open) [3].

RAD51C is an inclusion eligibility criterion in 19 clinical trials for ovarian carcinoma, of which 15 are open and 4 are closed. Of the trials that contain RAD51C status and ovarian carcinoma as inclusion criteria, 5 are phase 1 (4 open), 4 are phase 1/phase 2 (3 open), 8 are phase 2 (7 open), 1 is phase 3 (0 open), and 1 is phase 4 (1 open) [3].

RAD51D is an inclusion eligibility criterion in 18 clinical trials for ovarian carcinoma, of which 14 are open and 4 are closed. Of the trials that contain RAD51D status and ovarian carcinoma as inclusion criteria, 5 are phase 1 (4 open), 4 are phase 1/phase 2 (3 open), 7 are phase 2 (6 open), 1 is phase 3 (0 open), and 1 is phase 4 (1 open) [3].

RAD54L is an inclusion eligibility criterion in 16 clinical trials for ovarian carcinoma, of which 12 are open and 4 are closed. Of the trials that contain RAD54L status and ovarian carcinoma as inclusion criteria, 5 are phase 1 (4 open), 3 are phase 1/phase 2 (2 open), 6 are phase 2 (5 open), 1 is phase 3 (0 open), and 1 is phase 4 (1 open) [3].

RAF1 is an inclusion eligibility criterion in 3 clinical trials for ovarian carcinoma, of which 3 are open and 0 are closed. Of the trials that contain RAF1 status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

RB1 is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 0 are open and 1 is closed. Of the trial that contains RB1 status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

RET is an inclusion eligibility criterion in 2 clinical trials for ovarian carcinoma, of which 2 are open and 0 are closed. Of the trials that contain RET status and ovarian carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

RFC1 is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RFC1 status and ovarian carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RFC2 is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RFC2 status and ovarian carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RFC3 is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RFC3 status and ovarian carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RFC4 is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RFC4 status and ovarian carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RFC5 is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RFC5 status and ovarian carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RICTOR is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RICTOR status and ovarian carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

ROS1 is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ROS1 status and ovarian carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RPA1 is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RPA1 status and ovarian carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RPA2 is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RPA2 status and ovarian carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RPA3 is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RPA3 status and ovarian carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RPA4 is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RPA4 status and ovarian carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RPTOR is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RPTOR status and ovarian carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

RUNX1 is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 0 are open and 1 is closed. Of the trial that contains RUNX1 status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

SETD2 is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 0 are open and 1 is closed. Of the trial that contains SETD2 status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

SLX4 is an inclusion eligibility criterion in 13 clinical trials for ovarian carcinoma, of which 9 are open and 4 are closed. Of the trials that contain SLX4 status and ovarian carcinoma as inclusion criteria, 5 are phase 1 (4 open), 2 are phase 1/phase 2 (1 open), 5 are phase 2 (4 open), and 1 is phase 3 (0 open) [3].

SMARCA4 is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 0 are open and 1 is closed. Of the trial that contains SMARCA4 status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

SMARCB1 is an inclusion eligibility criterion in 4 clinical trials for ovarian carcinoma, of which 3 are open and 1 is closed. Of the trials that contain SMARCB1 status and ovarian carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 1 is phase 1/phase 2 (0 open) [3].

SOX9 is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 0 are open and 1 is closed. Of the trial that contains SOX9 status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

SRC is an inclusion eligibility criterion in 2 clinical trials for ovarian carcinoma, of which 2 are open and 0 are closed. Of the trials that contain SRC status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

SSBP1 is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains SSBP1 status and ovarian carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

STAG2 is an inclusion eligibility criterion in 5 clinical trials for ovarian carcinoma, of which 3 are open and 2 are closed. Of the trials that contain STAG2 status and ovarian carcinoma as inclusion criteria, 4 are phase 1 (3 open) and 1 is phase 1/phase 2 (0 open) [3].

STK11 is an inclusion eligibility criterion in 5 clinical trials for ovarian carcinoma, of which 4 are open and 1 is closed. Of the trials that contain STK11 status and ovarian carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 2 are phase 1/phase 2 (1 open) [3].

TAF1 is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 0 are open and 1 is closed. Of the trial that contains TAF1 status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

TBX3 is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 0 are open and 1 is closed. Of the trial that contains TBX3 status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

TET2 is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 0 are open and 1 is closed. Of the trial that contains TET2 status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

TP53 is an inclusion eligibility criterion in 7 clinical trials for ovarian carcinoma, of which 2 are open and 5 are closed. Of the trials that contain TP53 status and ovarian carcinoma as inclusion criteria, 2 are phase 1 (0 open), 2 are phase 1/phase 2 (0 open), and 3 are phase 2 (2 open) [3].

TSC1 is an inclusion eligibility criterion in 2 clinical trials for ovarian carcinoma, of which 2 are open and 0 are closed. Of the trials that contain TSC1 status and ovarian carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

TSC2 is an inclusion eligibility criterion in 2 clinical trials for ovarian carcinoma, of which 2 are open and 0 are closed. Of the trials that contain TSC2 status and ovarian carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

VHL is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains VHL status and ovarian carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

XPO1 is an inclusion eligibility criterion in 1 clinical trial for ovarian carcinoma, of which 0 are open and 1 is closed. Of the trial that contains XPO1 status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

XRCC1 is an inclusion eligibility criterion in 4 clinical trials for ovarian carcinoma, of which 3 are open and 1 is closed. Of the trials that contain XRCC1 status and ovarian carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 1 is phase 1/phase 2 (0 open) [3].